These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 20960212)

  • 1. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.
    Schalkwijk CG; Miyata T
    Amino Acids; 2012 Apr; 42(4):1193-204. PubMed ID: 20960212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
    Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
    Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiological role of Amadori-glycated proteins in diabetic microangiopathy.
    Schalkwijk CG; Lieuw-a-Fa M; van Hinsbergh VW; Stehouwer CD
    Semin Vasc Med; 2002 May; 2(2):191-7. PubMed ID: 16222610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-enzymatic glycation of proteins: from diabetes to cancer].
    Ansari NA; Rasheed Z
    Biomed Khim; 2010; 56(2):168-78. PubMed ID: 21341505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between the sorbitol pathway, non-enzymatic glycation, and diabetic vascular dysfunction.
    Ido Y; Kilo C; Williamson JR
    Nephrol Dial Transplant; 1996; 11 Suppl 5():72-5. PubMed ID: 9044312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation endproducts and diabetes. Beyond vascular complications.
    Puddu A; Viviani GL
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):132-40. PubMed ID: 21476962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
    Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
    Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
    Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
    Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
    Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
    Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
    Takeuchi M; Takino J; Yamagishi S
    Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
    Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
    Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors.
    Vlassara H; Bucala R
    Diabetes; 1996 Jul; 45 Suppl 3():S65-6. PubMed ID: 8674896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of advanced glycation in the pathogenesis of diabetic retinopathy.
    Stitt AW
    Exp Mol Pathol; 2003 Aug; 75(1):95-108. PubMed ID: 12834631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress in advanced glycation end products and diabetic complications.
    Vlassara H
    Diabetes; 1997 Sep; 46 Suppl 2():S19-25. PubMed ID: 9285494
    [No Abstract]   [Full Text] [Related]  

  • 15. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes.
    Schmidt AM; Stern DM
    Trends Endocrinol Metab; 2000 Nov; 11(9):368-75. PubMed ID: 11042467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of diabetic angiopathy--clues for innovative therapeutic interventions.
    Bierhaus A; Ziegler R; Nawroth PP
    Horm Res; 1998; 50 Suppl 1():1-5. PubMed ID: 9676989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.
    Lee J; Yun JS; Ko SH
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35956261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Possible participation of advanced glycation endproducts and their receptor system in the development of diabetic vascular complications].
    Yamamoto Y; Sakurai S; Watanabe T; Yonekura H; Yamamoto H
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):49-55. PubMed ID: 12617038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy.
    Yoon SJ; Yoon YW; Lee BK; Kwon HM; Hwang KC; Kim M; Chang W; Hong BK; Lee YH; Park SJ; Min PK; Rim SJ
    Exp Mol Med; 2009 Nov; 41(11):802-11. PubMed ID: 19641377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
    Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
    Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.